Setback for AnGes MG as it pulls key Japanese filing
This article was originally published in Scrip
Executive Summary
AnGes MG has withdrawn a regulatory filing in Japan for its lead therapeutic product, in a move that looks set to put back by several years the likely approval of the gene-based biologic.